These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35519174)

  • 41. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
    Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Dechates B; Monprach H; Sornsamdang G; Wittayasak K; Soonklang K; Mahanonda N
    Hum Vaccin Immunother; 2022 Dec; 18(1):2035573. PubMed ID: 35240945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Race for Global Equitable Access to COVID-19 Vaccines.
    Md Khairi LNH; Fahrni ML; Lazzarino AI
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.
    Zamai L; Rocchi MBL
    Br J Pharmacol; 2022 Jan; 179(2):218-226. PubMed ID: 34331459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
    Schmidt T; Klemis V; Schub D; Mihm J; Hielscher F; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Schneitler S; Becker SL; Gärtner BC; Sester U; Sester M
    Nat Med; 2021 Sep; 27(9):1530-1535. PubMed ID: 34312554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India.
    Kaur U; Bala S; Ojha B; Jaiswal S; Kansal S; Chakrabarti SS
    J Med Virol; 2022 Jan; 94(1):407-412. PubMed ID: 34491572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
    Smolenov I; Han HH; Li P; Baccarini C; Verhoeven C; Rockhold F; Clemens SAC; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R;
    Lancet Infect Dis; 2022 Jul; 22(7):990-1001. PubMed ID: 35447085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
    Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
    Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
    Westrop SJ; Whitaker HJ; Powell AA; Power L; Whillock C; Campbell H; Simmons R; Warrener L; Ramsay ME; Ladhani SN; Brown KE; Amirthalingam G
    J Infect; 2022 May; 84(5):692-700. PubMed ID: 35131335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Revival of the heterologous prime-boost technique in COVID-19: An outlook from the history of outbreaks.
    Siddiqui A; Adnan A; Abbas M; Taseen S; Ochani S; Essar MY
    Health Sci Rep; 2022 Mar; 5(2):e531. PubMed ID: 35229055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
    Watson OJ; Barnsley G; Toor J; Hogan AB; Winskill P; Ghani AC
    Lancet Infect Dis; 2022 Sep; 22(9):1293-1302. PubMed ID: 35753318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risky business: COVAX and the financialization of global vaccine equity.
    Stein F
    Global Health; 2021 Sep; 17(1):112. PubMed ID: 34544439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. COVID-19 vaccine inequity in African low-income countries.
    Kunyenje CA; Chirwa GC; Mboma SM; Ng'ambi W; Mnjowe E; Nkhoma D; Ngwira LG; Chawani MS; Chilima B; Mitambo C; Crampin A; Mfutso-Bengo J
    Front Public Health; 2023; 11():1087662. PubMed ID: 36950103
    [TBL] [Abstract][Full Text] [Related]  

  • 58. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.
    Bright B; Babalola CP; Sam-Agudu NA; Onyeaghala AA; Olatunji A; Aduh U; Sobande PO; Crowell TA; Tebeje YK; Phillip S; Ndembi N; Folayan MO
    Global Health; 2021 Mar; 17(1):24. PubMed ID: 33658050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccine inequity: a threat to Africa's recovery from COVID-19.
    Wei CR; Kamande S; Lang'at GC
    Trop Med Health; 2023 Dec; 51(1):69. PubMed ID: 38111032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap.
    Borges LC; Zeferino de Menezes H; Crosbie E
    Int J Health Policy Manag; 2022 Dec; 11(12):3101-3113. PubMed ID: 36028975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.